patient_id stringlengths 12 12 | record_id stringlengths 11 11 | cancer_type stringclasses 1
value | histology stringclasses 3
values | stage_at_diagnosis stringclasses 3
values | driver_mutation stringclasses 7
values | pd_l1_tps_percent int64 5 41 | tmb_mutations_per_mb float64 1.5 25 | age_at_diagnosis int64 38 90 | sex stringclasses 2
values | ecog_performance_status int64 0 4 | smoking_pack_years int64 0 111 | primary_tumor_size_cm float64 2 10 | metastatic_sites_count int64 0 11 | first_line_regimen stringclasses 6
values | overall_survival_months float64 4 83 | censored bool 2
classes | msi_status stringclasses 2
values | record_generation_timestamp stringdate 2026-03-15 05:35:56 2026-03-15 05:36:02 | synthetic_source stringclasses 1
value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ANODE_238845 | REC_0008401 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 22 | 4.9 | 71 | female | 1 | 16 | 5.2 | 2 | pembrolizumab 200 mg q3w | 20.9 | false | MSS | 2026-03-15T05:35:58.924384+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_288369 | REC_0008402 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 15.7 | 78 | female | 3 | 8 | 4.4 | 7 | entrectinib 600 mg daily | 6.7 | false | MSI-H | 2026-03-15T05:35:58.924633+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_355584 | REC_0008403 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 17 | 7.2 | 66 | male | 1 | 42 | 8.6 | 6 | carboplatin + paclitaxel + pembrolizumab | 13.2 | false | MSS | 2026-03-15T05:35:58.924869+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_303747 | REC_0008404 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 29 | 10.4 | 90 | female | 1 | 9 | 4.2 | 2 | osimertinib 80 mg daily | 18.9 | true | MSS | 2026-03-15T05:35:58.925107+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_108614 | REC_0008405 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 28 | 15.6 | 60 | male | 0 | 23 | 4 | 4 | osimertinib 80 mg daily | 5.1 | true | MSS | 2026-03-15T05:35:58.925347+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_647675 | REC_0008406 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 25 | 9.8 | 74 | female | 2 | 7 | 6.4 | 6 | alectinib 600 mg BID | 12.4 | false | MSS | 2026-03-15T05:35:58.925575+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_380098 | REC_0008407 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 31 | 8.7 | 66 | female | 1 | 6 | 5.2 | 1 | osimertinib 80 mg daily | 12.4 | true | MSS | 2026-03-15T05:35:58.925804+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_183681 | REC_0008408 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 8.4 | 66 | female | 0 | 70 | 4 | 4 | carboplatin + paclitaxel + pembrolizumab | 14.1 | true | MSS | 2026-03-15T05:35:58.926041+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_370653 | REC_0008409 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 26 | 5.2 | 64 | female | 1 | 63 | 4.4 | 7 | carboplatin + paclitaxel + pembrolizumab | 9.6 | true | MSS | 2026-03-15T05:35:58.926274+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_791444 | REC_0008410 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 27 | 4.4 | 89 | male | 2 | 8 | 3 | 7 | pembrolizumab 200 mg q3w | 13.2 | false | MSS | 2026-03-15T05:35:58.926511+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_233059 | REC_0008411 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 26 | 14.7 | 69 | female | 0 | 15 | 5.7 | 1 | osimertinib 80 mg daily | 23.5 | true | MSS | 2026-03-15T05:35:58.926747+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_998650 | REC_0008412 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 6.4 | 77 | female | 1 | 13 | 5.8 | 1 | alectinib 600 mg BID | 26.4 | false | MSS | 2026-03-15T05:35:58.927041+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_324301 | REC_0008413 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 25 | 5.1 | 66 | female | 0 | 25 | 7.3 | 1 | pembrolizumab 200 mg q3w | 16.7 | false | MSS | 2026-03-15T05:35:58.927278+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_909266 | REC_0008414 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 16 | 4.5 | 74 | female | 0 | 61 | 5.7 | 1 | carboplatin + paclitaxel + pembrolizumab | 26.2 | false | MSS | 2026-03-15T05:35:58.927506+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_673749 | REC_0008415 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 26 | 6.1 | 46 | male | 0 | 58 | 5.4 | 2 | carboplatin + paclitaxel + pembrolizumab | 15.8 | false | MSS | 2026-03-15T05:35:58.927741+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_965803 | REC_0008416 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 26 | 11 | 56 | female | 0 | 0 | 6.6 | 3 | sotorasib 960 mg daily | 10.3 | false | MSI-H | 2026-03-15T05:35:58.927977+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_248885 | REC_0008417 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 19 | 13.9 | 79 | female | 2 | 15 | 6.8 | 3 | osimertinib 80 mg daily | 4.9 | true | MSS | 2026-03-15T05:35:58.928245+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_537923 | REC_0008418 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 17.8 | 62 | male | 1 | 13 | 6.1 | 6 | osimertinib 80 mg daily | 13.6 | true | MSI-H | 2026-03-15T05:35:58.928485+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_227648 | REC_0008419 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 10.6 | 79 | female | 1 | 18 | 3.3 | 8 | entrectinib 600 mg daily | 11.1 | true | MSI-H | 2026-03-15T05:35:58.928721+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_231312 | REC_0008420 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 19 | 10.2 | 56 | male | 0 | 38 | 4.6 | 2 | carboplatin + paclitaxel + pembrolizumab | 21.9 | true | MSS | 2026-03-15T05:35:58.928957+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_177161 | REC_0008421 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 22 | 12.9 | 76 | female | 2 | 12 | 3.5 | 8 | osimertinib 80 mg daily | 4.2 | false | MSS | 2026-03-15T05:35:58.929194+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_802045 | REC_0008422 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 16 | 12.1 | 60 | female | 0 | 17 | 5.5 | 2 | osimertinib 80 mg daily | 12.3 | false | MSI-H | 2026-03-15T05:35:58.929427+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_883150 | REC_0008423 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 21 | 13.3 | 69 | female | 1 | 25 | 4.3 | 5 | pembrolizumab 200 mg q3w | 10.4 | false | MSI-H | 2026-03-15T05:35:58.929660+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_134308 | REC_0008424 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 21 | 16.6 | 52 | female | 0 | 9 | 5.2 | 7 | osimertinib 80 mg daily | 8.2 | true | MSS | 2026-03-15T05:35:58.929895+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_412577 | REC_0008425 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 21 | 5.5 | 67 | female | 0 | 46 | 4.8 | 1 | carboplatin + paclitaxel + pembrolizumab | 14.6 | true | MSS | 2026-03-15T05:35:58.930174+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_637062 | REC_0008426 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 31 | 13.7 | 51 | female | 0 | 14 | 5.3 | 2 | pembrolizumab 200 mg q3w | 20.7 | true | MSS | 2026-03-15T05:35:58.930412+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_262086 | REC_0008427 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 20 | 10.1 | 70 | female | 1 | 7 | 4.7 | 1 | osimertinib 80 mg daily | 13.4 | true | MSI-H | 2026-03-15T05:35:58.930650+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_571198 | REC_0008428 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 28 | 7.1 | 66 | female | 0 | 26 | 4.8 | 5 | pembrolizumab 200 mg q3w | 15.5 | false | MSS | 2026-03-15T05:35:58.930882+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_951881 | REC_0008429 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 30 | 9.9 | 81 | female | 1 | 17 | 6.2 | 6 | osimertinib 80 mg daily | 11.4 | true | MSS | 2026-03-15T05:35:58.931112+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_887312 | REC_0008430 | Non-small cell lung cancer | Large cell carcinoma | IVB | None (PD-L1 high) | 19 | 3.8 | 76 | female | 3 | 15 | 6.1 | 4 | pembrolizumab 200 mg q3w | 17.7 | false | MSS | 2026-03-15T05:35:58.931339+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_155644 | REC_0008431 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 21 | 13.5 | 78 | female | 0 | 7 | 5.3 | 1 | pembrolizumab 200 mg q3w | 19.4 | true | MSS | 2026-03-15T05:35:58.931571+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_809349 | REC_0008432 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 26 | 8.5 | 73 | female | 2 | 16 | 5.3 | 6 | pembrolizumab 200 mg q3w | 14 | false | MSS | 2026-03-15T05:35:58.931802+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_366357 | REC_0008433 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 17 | 18.5 | 82 | female | 1 | 25 | 5.1 | 1 | alectinib 600 mg BID | 17 | false | MSI-H | 2026-03-15T05:35:58.932032+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_965200 | REC_0008434 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 6.8 | 85 | female | 2 | 45 | 4.1 | 4 | carboplatin + paclitaxel + pembrolizumab | 8.2 | true | MSS | 2026-03-15T05:35:58.932363+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_381112 | REC_0008435 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 33 | 11.5 | 58 | female | 0 | 15 | 4.4 | 3 | pembrolizumab 200 mg q3w | 7.2 | false | MSS | 2026-03-15T05:35:58.932609+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_110603 | REC_0008436 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 20 | 4.3 | 60 | female | 0 | 44 | 4.5 | 6 | carboplatin + paclitaxel + pembrolizumab | 5.4 | false | MSS | 2026-03-15T05:35:58.932846+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_553546 | REC_0008437 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 9.9 | 74 | female | 0 | 18 | 4.8 | 8 | sotorasib 960 mg daily | 4 | true | MSS | 2026-03-15T05:35:58.933078+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_352185 | REC_0008438 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 25 | 18.3 | 64 | male | 1 | 25 | 6.3 | 7 | osimertinib 80 mg daily | 11 | false | MSI-H | 2026-03-15T05:35:58.933367+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_976791 | REC_0008439 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 19 | 4.5 | 77 | female | 0 | 8 | 5.7 | 2 | entrectinib 600 mg daily | 18.3 | true | MSS | 2026-03-15T05:35:58.933605+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_859404 | REC_0008440 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 18 | 12.6 | 70 | female | 1 | 18 | 7.9 | 1 | alectinib 600 mg BID | 20.2 | true | MSS | 2026-03-15T05:35:58.933840+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_454747 | REC_0008441 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 29 | 6.6 | 86 | female | 2 | 18 | 4.7 | 1 | pembrolizumab 200 mg q3w | 24.5 | false | MSS | 2026-03-15T05:35:58.934070+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_683451 | REC_0008442 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 24 | 5.3 | 71 | female | 1 | 25 | 4.3 | 7 | carboplatin + paclitaxel + pembrolizumab | 4 | false | MSS | 2026-03-15T05:35:58.934300+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_904333 | REC_0008443 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 28 | 13.9 | 66 | female | 0 | 19 | 4.8 | 2 | osimertinib 80 mg daily | 11.2 | false | MSS | 2026-03-15T05:35:58.934538+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_728699 | REC_0008444 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 13.9 | 74 | female | 3 | 14 | 6.3 | 3 | osimertinib 80 mg daily | 8.3 | true | MSI-H | 2026-03-15T05:35:58.934772+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_509285 | REC_0008445 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 25 | 13 | 73 | female | 2 | 13 | 7.2 | 9 | osimertinib 80 mg daily | 9.5 | true | MSS | 2026-03-15T05:35:58.935004+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_771151 | REC_0008446 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 23 | 12.3 | 67 | female | 1 | 9 | 6.7 | 2 | alectinib 600 mg BID | 17.8 | false | MSI-H | 2026-03-15T05:35:58.935238+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_291421 | REC_0008447 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 20 | 12.5 | 83 | female | 2 | 23 | 4.7 | 1 | entrectinib 600 mg daily | 15.8 | false | MSS | 2026-03-15T05:35:58.935472+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_596242 | REC_0008448 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 23 | 13.8 | 65 | female | 0 | 7 | 5.8 | 5 | sotorasib 960 mg daily | 10.2 | true | MSS | 2026-03-15T05:35:58.935708+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_182209 | REC_0008449 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 29 | 13.9 | 79 | female | 2 | 21 | 6.4 | 2 | osimertinib 80 mg daily | 22.1 | false | MSI-H | 2026-03-15T05:35:58.935941+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_830025 | REC_0008450 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 31 | 14.9 | 71 | male | 1 | 11 | 5.4 | 2 | osimertinib 80 mg daily | 12.6 | true | MSS | 2026-03-15T05:35:58.936415+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_806892 | REC_0008451 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 18 | 15.6 | 70 | female | 2 | 11 | 3.4 | 7 | alectinib 600 mg BID | 8.7 | false | MSI-H | 2026-03-15T05:35:58.936721+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_172256 | REC_0008452 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 25 | 10.8 | 59 | female | 1 | 26 | 5 | 1 | alectinib 600 mg BID | 23.7 | true | MSS | 2026-03-15T05:35:58.936970+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_842632 | REC_0008453 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 22 | 9.5 | 58 | female | 1 | 15 | 6.2 | 1 | alectinib 600 mg BID | 18.6 | true | MSS | 2026-03-15T05:35:58.937209+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_578222 | REC_0008454 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 24 | 12.8 | 78 | male | 3 | 8 | 6.7 | 5 | sotorasib 960 mg daily | 17.2 | true | MSI-H | 2026-03-15T05:35:58.937453+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_790193 | REC_0008455 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 16 | 5.8 | 65 | female | 1 | 50 | 3.7 | 2 | carboplatin + paclitaxel + pembrolizumab | 15.8 | true | MSS | 2026-03-15T05:35:58.937688+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_734796 | REC_0008456 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 22 | 13.1 | 73 | female | 2 | 6 | 6.8 | 1 | sotorasib 960 mg daily | 17.8 | true | MSI-H | 2026-03-15T05:35:58.937923+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_548022 | REC_0008457 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 27 | 5.2 | 71 | female | 1 | 18 | 7.6 | 5 | carboplatin + paclitaxel + pembrolizumab | 9.9 | false | MSS | 2026-03-15T05:35:58.938150+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_766920 | REC_0008458 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 26 | 13.3 | 65 | female | 0 | 14 | 5.2 | 5 | osimertinib 80 mg daily | 9.8 | true | MSS | 2026-03-15T05:35:58.938387+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_135538 | REC_0008459 | Non-small cell lung cancer | Large cell carcinoma | IVA | None (PD-L1 high) | 28 | 8.6 | 61 | female | 1 | 22 | 6.8 | 2 | pembrolizumab 200 mg q3w | 13 | false | MSS | 2026-03-15T05:35:58.938620+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_878326 | REC_0008460 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None (PD-L1 high) | 25 | 6 | 78 | female | 2 | 59 | 4 | 8 | pembrolizumab 200 mg q3w | 4.5 | true | MSS | 2026-03-15T05:35:58.938851+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_527161 | REC_0008461 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 29 | 9.7 | 72 | male | 2 | 22 | 4.8 | 2 | osimertinib 80 mg daily | 6.8 | false | MSS | 2026-03-15T05:35:58.939082+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_232477 | REC_0008462 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 33 | 10.3 | 68 | female | 0 | 59 | 4.1 | 6 | carboplatin + paclitaxel + pembrolizumab | 9.4 | false | MSI-H | 2026-03-15T05:35:58.939314+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_566566 | REC_0008463 | Non-small cell lung cancer | Squamous cell carcinoma | IVA | None | 19 | 7 | 61 | female | 0 | 32 | 5.7 | 2 | carboplatin + paclitaxel + pembrolizumab | 22.2 | true | MSS | 2026-03-15T05:35:58.939550+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_909344 | REC_0008464 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 21 | 5.3 | 85 | female | 1 | 93 | 6.2 | 7 | carboplatin + paclitaxel + pembrolizumab | 13.3 | false | MSS | 2026-03-15T05:35:58.939821+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_327565 | REC_0008465 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 24 | 14.9 | 58 | female | 1 | 9 | 5 | 5 | pembrolizumab 200 mg q3w | 9.3 | true | MSI-H | 2026-03-15T05:35:58.940061+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_625379 | REC_0008466 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 25 | 10 | 78 | female | 0 | 10 | 6.8 | 6 | sotorasib 960 mg daily | 16.1 | true | MSI-H | 2026-03-15T05:35:58.940329+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_713809 | REC_0008467 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 19 | 7.5 | 71 | female | 2 | 35 | 4.3 | 4 | carboplatin + paclitaxel + pembrolizumab | 18.9 | true | MSS | 2026-03-15T05:35:58.940559+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_712625 | REC_0008468 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 14 | 13.6 | 65 | female | 1 | 11 | 4.6 | 5 | osimertinib 80 mg daily | 16.3 | false | MSS | 2026-03-15T05:35:58.940794+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_551519 | REC_0008469 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 29 | 12.1 | 63 | female | 1 | 16 | 4.6 | 7 | alectinib 600 mg BID | 13.1 | false | MSI-H | 2026-03-15T05:35:58.941029+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_321924 | REC_0008470 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 19 | 15.2 | 67 | female | 0 | 11 | 6.6 | 1 | osimertinib 80 mg daily | 11.8 | false | MSS | 2026-03-15T05:35:58.941262+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_709508 | REC_0008471 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 8.1 | 63 | male | 0 | 21 | 5.7 | 6 | alectinib 600 mg BID | 15.2 | false | MSS | 2026-03-15T05:35:58.941496+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_511064 | REC_0008472 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 21 | 10.8 | 71 | female | 1 | 34 | 5.1 | 1 | alectinib 600 mg BID | 11.6 | false | MSI-H | 2026-03-15T05:35:58.941727+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_557599 | REC_0008473 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 25 | 11.2 | 75 | female | 4 | 10 | 5.5 | 6 | pembrolizumab 200 mg q3w | 13.2 | false | MSI-H | 2026-03-15T05:35:58.941958+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_222669 | REC_0008474 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR L858R | 31 | 15 | 60 | female | 1 | 12 | 6.9 | 0 | osimertinib 80 mg daily | 18.8 | true | MSI-H | 2026-03-15T05:35:58.942192+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_744805 | REC_0008475 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 16 | 15.1 | 58 | male | 1 | 19 | 4.6 | 4 | pembrolizumab 200 mg q3w | 6.1 | true | MSI-H | 2026-03-15T05:35:58.942426+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_206263 | REC_0008476 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 31 | 3.9 | 79 | male | 1 | 11 | 3.5 | 1 | osimertinib 80 mg daily | 22.9 | true | MSS | 2026-03-15T05:35:58.942658+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_435166 | REC_0008477 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 32 | 11.6 | 61 | male | 1 | 25 | 5.2 | 5 | sotorasib 960 mg daily | 6.1 | false | MSS | 2026-03-15T05:35:58.942938+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_165420 | REC_0008478 | Non-small cell lung cancer | Adenocarcinoma | IVA | None (PD-L1 high) | 22 | 11.1 | 76 | female | 2 | 15 | 4.6 | 2 | pembrolizumab 200 mg q3w | 34.1 | false | MSS | 2026-03-15T05:35:58.943174+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_783278 | REC_0008479 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 23 | 9.2 | 51 | male | 0 | 17 | 5.3 | 2 | osimertinib 80 mg daily | 13.1 | false | MSS | 2026-03-15T05:35:58.943406+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_394827 | REC_0008480 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 35 | 17.8 | 72 | female | 2 | 12 | 4.1 | 1 | entrectinib 600 mg daily | 14.3 | true | MSI-H | 2026-03-15T05:35:58.943641+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_862206 | REC_0008481 | Non-small cell lung cancer | Adenocarcinoma | III | EGFR L858R | 33 | 10.1 | 76 | male | 3 | 28 | 7.8 | 0 | osimertinib 80 mg daily | 48.6 | false | MSS | 2026-03-15T05:35:58.943877+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_108165 | REC_0008482 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 23 | 10.6 | 64 | male | 0 | 2 | 6.3 | 6 | entrectinib 600 mg daily | 9.5 | false | MSS | 2026-03-15T05:35:58.944140+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_544121 | REC_0008483 | Non-small cell lung cancer | Adenocarcinoma | III | ROS1 fusion | 18 | 16.9 | 59 | male | 0 | 14 | 5.8 | 0 | entrectinib 600 mg daily | 62.2 | true | MSI-H | 2026-03-15T05:35:58.944385+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_698347 | REC_0008484 | Non-small cell lung cancer | Squamous cell carcinoma | III | None (PD-L1 high) | 19 | 3.8 | 66 | male | 1 | 43 | 5.9 | 0 | pembrolizumab 200 mg q3w | 30.4 | false | MSS | 2026-03-15T05:35:58.944618+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_777739 | REC_0008485 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 21 | 8 | 74 | male | 2 | 11 | 5.9 | 6 | alectinib 600 mg BID | 18 | false | MSS | 2026-03-15T05:35:58.944851+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_879273 | REC_0008486 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 26 | 10.3 | 57 | male | 1 | 11 | 5.4 | 6 | osimertinib 80 mg daily | 4 | true | MSS | 2026-03-15T05:35:58.945084+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_460118 | REC_0008487 | Non-small cell lung cancer | Adenocarcinoma | IVB | None (PD-L1 high) | 32 | 15 | 63 | female | 1 | 6 | 7 | 6 | pembrolizumab 200 mg q3w | 9.8 | true | MSI-H | 2026-03-15T05:35:58.945318+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_698134 | REC_0008488 | Non-small cell lung cancer | Adenocarcinoma | IVA | ROS1 fusion | 26 | 1.5 | 67 | female | 0 | 25 | 6.3 | 3 | entrectinib 600 mg daily | 9.3 | false | MSS | 2026-03-15T05:35:58.945547+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_461595 | REC_0008489 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 5.8 | 75 | male | 2 | 27 | 6.7 | 7 | carboplatin + paclitaxel + pembrolizumab | 17.8 | false | MSS | 2026-03-15T05:35:58.945777+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_235933 | REC_0008490 | Non-small cell lung cancer | Adenocarcinoma | IVB | ROS1 fusion | 17 | 15.6 | 56 | male | 1 | 20 | 6.6 | 5 | entrectinib 600 mg daily | 11.8 | false | MSS | 2026-03-15T05:35:58.946061+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_693608 | REC_0008491 | Non-small cell lung cancer | Adenocarcinoma | IVA | EGFR exon 19 deletion | 34 | 16.4 | 69 | male | 0 | 33 | 6.5 | 1 | osimertinib 80 mg daily | 17.6 | false | MSS | 2026-03-15T05:35:58.946303+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_329743 | REC_0008492 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR exon 19 deletion | 29 | 6.2 | 72 | female | 1 | 15 | 6.6 | 6 | osimertinib 80 mg daily | 14.7 | true | MSS | 2026-03-15T05:35:58.946535+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_489533 | REC_0008493 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 22 | 16.5 | 71 | female | 1 | 18 | 4.8 | 6 | osimertinib 80 mg daily | 11.6 | true | MSI-H | 2026-03-15T05:35:58.946766+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_788125 | REC_0008494 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 22 | 8.3 | 65 | male | 0 | 10 | 3.5 | 5 | alectinib 600 mg BID | 7.6 | false | MSS | 2026-03-15T05:35:58.946997+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_712205 | REC_0008495 | Non-small cell lung cancer | Adenocarcinoma | IVA | KRAS G12C | 28 | 14.2 | 73 | female | 2 | 20 | 4.2 | 1 | sotorasib 960 mg daily | 5.3 | true | MSI-H | 2026-03-15T05:35:58.947232+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_386582 | REC_0008496 | Non-small cell lung cancer | Squamous cell carcinoma | IVB | None | 25 | 10.3 | 71 | female | 2 | 46 | 6.2 | 5 | carboplatin + paclitaxel + pembrolizumab | 4 | true | MSI-H | 2026-03-15T05:35:58.947466+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_863974 | REC_0008497 | Non-small cell lung cancer | Adenocarcinoma | IVB | ALK fusion | 26 | 15.6 | 67 | female | 1 | 21 | 4.4 | 3 | alectinib 600 mg BID | 13.1 | true | MSS | 2026-03-15T05:35:58.947698+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_356185 | REC_0008498 | Non-small cell lung cancer | Adenocarcinoma | IVA | ALK fusion | 26 | 7.4 | 70 | female | 1 | 1 | 4.8 | 2 | alectinib 600 mg BID | 19.7 | true | MSS | 2026-03-15T05:35:58.947929+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_818197 | REC_0008499 | Non-small cell lung cancer | Adenocarcinoma | IVB | EGFR L858R | 23 | 9.4 | 86 | female | 1 | 27 | 5.6 | 5 | osimertinib 80 mg daily | 7.7 | true | MSS | 2026-03-15T05:35:58.948210+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
ANODE_723893 | REC_0008500 | Non-small cell lung cancer | Adenocarcinoma | IVB | KRAS G12C | 28 | 9.4 | 60 | female | 1 | 7 | 4.2 | 5 | sotorasib 960 mg daily | 12 | true | MSS | 2026-03-15T05:35:58.948459+00:00 | Grok-4 high-fidelity EHR/Genomics simulator v2025.2 (Gaussian noise applied) |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.